About the Authors

Alastair J. King

Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America

Marc R. Arnone

Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America

Maureen R. Bleam

Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America

Katherine G. Moss

Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America

Jingsong Yang

Affiliation GlaxoSmithKline Department of Enzymology & Mechanistic Pharmacology, Collegeville, Pennsylvania, United States of America

Kelly E. Fedorowicz

Affiliation GlaxoSmithKline Department of Enzymology & Mechanistic Pharmacology, Collegeville, Pennsylvania, United States of America

Kimberly N. Smitheman

Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America

Joseph A. Erhardt

Current address: Janssen Oncology R&D, Radnor, Pennsylvania, United States of America

Affiliation GlaxoSmithKline Portfolio Management, Collegeville, Pennsylvania, United States of America

Angela Hughes-Earle

Affiliation GlaxoSmithKline Department of Safety Assessment, King of Prussia, Pennsylvania, United States of America

Laurie S. Kane-Carson

Affiliation GlaxoSmithKline Department of Screening & Compound Profiling, GlaxoSmithKline, Durham, North Carolina, United States of America

Robert H. Sinnamon

Affiliation GlaxoSmithKline Department of Biological Reagents & Assay Development, King of Prussia, Pennsylvania, United States of America

Hongwei Qi

Affiliation GlaxoSmithKline Department of Biological Reagents & Assay Development, King of Prussia, Pennsylvania, United States of America

Tara R. Rheault

Affiliation GlaxoSmithKline Department of Medicinal Chemistry, GlaxoSmithKline, Durham, North Carolina, United States of America

David E. Uehling

Current address: Ontario Institute for Cancer Research, MaRS Centre, Toronto, Ontario, Canada

Affiliation GlaxoSmithKline Department of Medicinal Chemistry, GlaxoSmithKline, Durham, North Carolina, United States of America

Sylvie G. Laquerre

sylvie.g.laquerre@gsk.com

Affiliation GlaxoSmithKline Department of Oncology Biology, Collegeville, Pennsylvania, United States of America

Competing Interests

The authors are specifying that at the time the research was performed, all authors were GlaxoSmithKline (GSK) employees and received compensation from GSK. GSK also funded the research and financed patent applications linked to the discoveries described in the manuscript. GSK intends to commercialize dabrafenib, pending approval. GSK will adhere to all the PLOS ONE policies on sharing data and materials for non-human research purposes.

Author Contributions

Conceived and designed the experiments: AJK MRA MRB JY JAE SGL TRR DEU. Performed the experiments: MRA MRB KGM JY KEF KNS AHE LSKC RHS HQ. Analyzed the data: AJK AHE SGL. Contributed reagents/materials/analysis tools: TRR DEU. Wrote the paper: AJK SGL.